Clinical Study to Evaluate the Safety and Effectiveness of the Treatment With Tixel C on Acne Scars

Inclusion Criteria: 1. The Subjects will have atrophic mild to severe acne scars. 2. Male or female subjects, age 18-65 years old. 3. The subjects will have Fitzpatrick Skin Types I-VI. 4. Willingness and ability to provide written informed consent, including photo consent and adherence to photography procedures (i.e., removal of jewelry and makeup), prior to the study. 5. Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study. 6. Females post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide, or abstinence). Exclusion Criteria: 1. Subjects pregnant or planning to become pregnant, or have given birth less than three months ago or breast feeding. 2. Subjects with significant exposure to ultraviolet light. 3. Use of drugs that may induce hyperpigmentation such as amiodarone, clofazinmine, minocycline or chloroquine. 4. History of facial acne scar treatments with laser, surgical, chemical, light based or radiofrequency facial treatments. 5. Microdermabrasion, or prescription level glycolic acid treatments within three months prior to study participation. 6. Active HSV-1. May be enrolled only after a prophylactic regime has been followed prior to treatment and according to the Investigator's discretion. 7. History of keloid formation. 8. Permanent facial implant over area of treatment. 9. Injectable filler in area to be treated within nine months of investigation. 10. History of collagen vascular disease. 11. Subjects who have an impaired immune system, suffer from immunosuppressive diseases or are actively on immunosuppressive medications. 12. Subjects currently taking or have taken an oral retinoid in the past six months. 13. Subjects currently taking long-term oral steroid treatment 14. Subjects with any skin pathology which can induce bullous lesions, urticaria, or demonstrate a Koebner phenomenon (psoriasis, lichen planus, etc.). 15. History of autoimmune disease. 16. History of any disease that inhibits pain sensation. 17. History of Diabetes I or II. 18. Concurrent therapy that, in the principal investigator's opinion, would interfere with the evaluation of the safety or effectiveness of the study treatment. 19. Subjects who, in the Investigator's opinion, have a history of poor cooperation, non-compliance with medical treatment or unreliability. 20. Enrollment in any active study involving the use of investigational devices or drugs who in the Investigator's opinion would interfere with the evaluation of the current investigative device. 21. Any other contraindication stated in the guidance documents of the treatment device. 22. Any existing skin disease that in the investigator's opinion would interfere with the evaluation of the safety of the study treatment and any other cause per the principal investigator's discretion. 23. Hypertrophic facial acne scarring or other hypertrophic scarring. 24. Failure to acquire adequate baseline and final photography.